LLC (Fig. 2b, c) or B16-F10 (Supplementary Fig. 10B–D) allografted mice treated with either of the two Cds2 vMOs show decreased tumor volume and decreased final tumor weight compared to control vMO-injected mice. This evidence concerns the gene CDS2 and neoplasm.